| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.04 | 0.00 (-1.15%) | 0.0381 - 0.32 | 386.3 thousand (Below Avg) |
Market data as of 3:59PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 0.04 |
|---|---|
| Previous Close | 0.04 |
| Day's Range | 0.04 - 0.05 |
| Market Cap | 6.3M |
| Avg Volume (10 Day) | 765.9K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.08 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Fail |
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
Business Wire - Thursday 05/16/2013 8:30 AM ET
Senesco Announces Presentation on Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma
Business Wire - Tuesday 05/14/2013 8:30 AM ET
Senesco Announces $1.255 Million Equity Financing
Business Wire - Thursday 05/09/2013 1:06 PM ET
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
Business Wire - Monday 05/06/2013 8:30 AM ET
Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial
Business Wire - Monday 04/22/2013 8:30 AM ET
| SNTI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 71.35 |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| Opexa Therapeutics Inc | 1.67 | -4.02% |
| Reliv International Inc | 1.26 | -2.32% |
| Cardium Therapeutics Inc | 0.09 | -3.73% |
| Merus Labs International Inc | 0.56 | -1.75% |
Data is delayed by at least 15 min.